Adopting new drug-delivery technologies requires a well-defined strategy in order to mitigate the risk of product failure.
Such a plan must facilitate go/no-go decisions and adaptation during development. Ultimately, of course, to be successful,
a product must clear many hurdles, including efficacy and safety, acceptance by patients and doctors, the ability to secure
reimbursement, and manufacturing feasibility. Recent industry examples have magnified how critical such a strategy is. When
done well, innovation in drug delivery can reap rewards and benefits on many levels. Many patents on products in use today
are about to expire. Add to that both the greater use of biologics—with their large molecules that preclude traditional oral
delivery—and the trend toward personalized medicince requiring highly targeted therapeutics, and it's clear why there is a
growing need for delivery mechanisms that can do more than simply deposit small molecules into the bloodstream for distribution.
US sales of advanced drug-delivery systems were more than $54.2 billion in 2004. In 2005, they reached $64.1 billion, and
they grew to $74.4 billion by the end of 2006. Over the next five years, the market is expected to grow at an average annual
rate of 15.6 percent to reach $153.5 billion by 2011, according to an October 2006 BCC Research report.
The lead driver of this growth is demand: Some 40 percent of new chemical entities are rejected because of poor biopharmaceutical
properties, according to the Food and Drug Administration. In some cases, these obstacles can be overcome by use of novel
drug-delivery systems or devices. For example, a small biotech developing a recombinant protein drug, such as insulin or erythropoietin,
may know that its product cannot be given orally because it breaks down too quickly in the upper GI tract or because the molecule's
pH prevents it from being absorbed by the lower GI tract.
Rather than investing research dollars in trying to develop an enteric oral formulation that may still produce variable bioavailability,
it may be more prudent to invest in buccal (through the cheek), sublingual (under the tongue), or inhalation routes for better
absorption and efficacy. Certain therapeutic agents, such as stem cells or gene therapy, frequently require the use of delivery
devices to target the agent to a particular organ.
Top Developments in Oral Drug Delivery
Larger pharmaceutical companies also depend on innovative drug-delivery systems. For example, when a drug is facing patent
expiration and challenges by generic competitors, reformulating it with a new mode of delivery may enhance consumer appeal
and provide more rapid onset of action as well as better outcomes. These improvements can translate into greater sales without
the overwhelming costs of bringing a new drug molecule to market.
Top Developments in Parenteral Drug Delivery
In fact, advances are being made in many areas of drug administration (see "Five of a Kind"). Oral delivery mechanisms are
benefiting from progress in microencapsulation technologies for controlled, delayed, and extended release of drugs. For parenteral
(via injection or IV) administration, there is a focus on developing extended release or depot forms of drugs, so a biweekly
or monthly subcutaneous or intramuscular injection can provide a steady release of drug. Such administration allows for better
therapeutic control and patient compliance. (For more on specific innovations in oral and parenteral drug-delivery technology.)
Top Developments in Transdermal Drug Delivery